St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties
Tóm tắt
The chemical composition of St. John's wort has been well-studied. Documented pharmacological activities, including antidepressant, antiviral, and antibacterial effects, provide supporting evidence for several of the traditional uses stated for St John's wort. Many pharmacological activities appear to be attributable to hypericin and to the flavonoid constituents; hypericin is also reported to be responsible for the photosensitive reactions that have been documented for St. John's wort. With regard to the antidepressant effects of St John's wort, hyperforin, rather than hypericin as originally thought, has emerged as one of the major constituents responsible for antidepressant activity. Further research is required to determine which other constituents contribute to the antidepressant effect.
Evidence from randomised controlled trials has confirmed the efficacy of St John's wort extracts over placebo in the treatment of mild-to-moderately severe depression. Other randomised controlled studies have provided some evidence that St John's wort extracts are as effective as some standard antidepressants in mild-to-moderate depression. There is still a need for further trials to assess the efficacy of St John's wort extracts, compared with that of standard antidepressants, particularly newer antidepressant agents, such as the selective serotonin reuptake inhibitors (recent comparative studies with fluoxetine and sertraline have been conducted). Also, there is a need for further studies in well-defined groups of patients, in different types of depression, and conducted over longer periods in order to determine long-term safety. St John's wort does appear to have a more favourable short-term safety profile than do standard antidepressants, a factor that is likely to be important in patients continuing to take medication.
Concerns have been raised over interactions between St John's wort and certain prescribed medicines (including warfarin, ciclosporin, theophylline, digoxin, HIV protease inhibitors, anticonvulsants, selective serotonin reuptake inhibitors, triptans, oral contraceptives); advice is that patients taking these medicines should stop taking St John's wort, generally after seeking professional advice as dose adjustment of conventional treatment may be necessary.
Từ khóa
Tài liệu tham khảo
Agostinis, 1995, Photosensitized inhibition of growth factor regulated protein kinases by hypericin, Biochem. Pharmacol., 49, 1615, 10.1016/0006-2952(95)00097-J
Albrecht, 1994, St John's wort extract in the treatment of depression: observations of the use of Jarsin capsules, Der Kassenarzt, 41, 45
American Herbal Pharmacopeia, 1997, St John's wort
1979, Toxic reactions to plant products sold in health food stores, Med. Lett. Drugs Ther., 21, 29
1995, Hypericin improves blood safety, Scrip, 2005, 27
1995, Hypericin HIV trial in Thailand, Scrip, 2019, 25
2000, CSM advice on St John's wort, Pharm. J., 264, 358
Ayuga, 1986, A comparative study of phenolic acids of Hypericum caprifolium Boiss and Hypericum perforatum L, An. Real Acad. Farm., 52, 723
Baillie, 1997, Hypericum - four hypersensitivity reactions, The Modern Phytotherapist, 3, 24
Ballenger, 1979, Alcohol and central serotonin metabolism in man, Arch Gen Psych Scand, 57, 224, 10.1001/archpsyc.1979.01780020114013
Barbenel, 2000, Mania in a patient receiving testosterone replacement post-orchidectomy taking St John's wort and sertraline, J. Psychopharmacol., 14, 84, 10.1177/026988110001400113
Barnes, 2000, Herbal medicines
Barone, 2000, Drug interaction between St John's wort and cyclosporine, Ann. Pharmacother., 34, 1013, 10.1345/aph.10088
Beckman, 2000, Consumer use of St John's wort: a survey on effectiveness, safety and tolerability, Pharmacotherapy, 20, 568, 10.1592/phco.20.6.568.35152
Berghöfer, 1987, Biflavonoids in Hypericum perforatum; Part 1. Isolation of 13,II8-biapigenin, Planta Med., 53, 216, 10.1055/s-2006-962676
Berghöfer, 1989, Isolation of I3′,II8-biapigenin (amentoflavone) from Hypericum perforatum, Planta Med., 55, 91, 10.1055/s-2006-961839
Bezáková, 1999, Effect of dianthrones and their precursors from Hypericum perforatum L. on lipoxygenase activity, Pharmazie, 54, 711
Biber, 1998, Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers, Pharmacopsychiatry, 31, 36, 10.1055/s-2007-979344
Bisset, 1994, Herbal Drugs and Phytopharmaceuticals, German edition
Bladt, 1994, Inhibition of MAO by fractions and constituents of Hypericum extract, J Geriatric Psychiatry Neurology, 7, S57, 10.1177/089198879400700115
Boblitz, 2000, Benefit of a fixed drug combination containing St John's wort and black cohosh for climacteric patients - results of a randomised clinical trial [abstract], FACT, 5, 85, 10.1111/j.2042-7166.2000.tb02340.x
Bombardelli, 1995, Hypericum perforatum, Fitoterapia, 66, 43
Bork, 1999, Hypericin as a non-oxidant inhibitor of NF-κB, Planta Med., 65, 297, 10.1055/s-1999-13989
Bove, 1998, Acute neuropathy after exposure to sun in a patient treated with St John's wort, Lancet, 352, 1121, 10.1016/S0140-6736(05)79763-4
Breckenridge, 2000, Important interactions between St John's wort (Hypericum perforatum) preparations and prescribed medicines
Breidenbach, 2000, Drug interaction of St John's wort with ciclosporin, Lancet, 355, 1912, 10.1016/S0140-6736(05)73359-6
Brenner, 2000, Comparison of an extract of hypericum (LI160) and sertraline in the treatment of depression: a double-blind, randomized pilot study, Clin. Ther., 22, 411, 10.1016/S0149-2918(00)89010-4
Brevoort, 1998, The booming US botanical market. A new overview, Herbalgram, 44, 33
British Herbal Pharmacopoeia, 1996, Exeter: British Herbal Medicine Association
Brockmöller, 1997, Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans, Pharmacopsychiatry, 30, 94, 10.1055/s-2007-979527
Brondz, 1982, The relative stereochemistry of hyperforin - An antibiotic from Hypericum perforatum L, Tetrahedron Lett., 123, 1299, 10.1016/S0040-4039(00)87088-4
Brondz, 1983, n-Alkanes of Hypericum perforatum: A revision, Phytochemistry, 22, 295, 10.1016/S0031-9422(00)80110-7
Butterweck, 2000, Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test, Planta Med., 66, 3, 10.1055/s-2000-11119
Calapai, 1999, Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat, J. Pharm. Pharmacol., 51, 723, 10.1211/0022357991772862
Chatterjee, 1998, Hyperforin as a possible antidepressant component of hypericum extracts, Life Sci., 63, 499, 10.1016/S0024-3205(98)00299-9
Chatterjee, 1998, Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility, Pharmacopsychiatry, 31, 7, 10.1055/s-2007-979340
Chung, 2000, Intratumoral hypericin and KTP laser therapy for transplanted squamous cell carcinoma, Laryngoscope, 110, 1312, 10.1097/00005537-200008000-00016
Colasanti, 2000, Hypericin photo-sensitization of tumor and metastatic cell lines of human prostate, J. Photochem. Photobiol. B., 54, 103, 10.1016/S1011-1344(99)00149-9
Colker, 1999, Effects of Citrus aurantium extract, caffeine, and St John's wort on body fat loss, lipid levels, and mood states in overweight healthy adults, Curr. Ther. Res., 60, 145, 10.1016/S0011-393X(00)88523-9
Cooper, 1990, An observational study of the safety and efficacy of hypericin in HIV-positive subjects [abstract], International Conference on AIDS, 6, 369
Cott, 1997, In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract, Pharmacopsychiatry, 30, 108, 10.1055/s-2007-979529
Council of Europe, 2000, Natural sources of Flavourings
Demisch, 1989, Identification of MAO-type-A inhibitors in Hypericum perforatum L. (Hyperforat), Pharmacopsychiatry, 22, 194
De Vry, 1999, Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism, Eur. Neuropsychopharmacol., 9, 461, 10.1016/S0924-977X(99)00005-X
De Witte, 1993, Inhibition of epidermal growth factor receptor tyrosine kinase activity by hypericin, Biochem. Pharmacol., 46, 1929, 10.1016/0006-2952(93)90633-8
Dorossiev, 1985, Determination of flavonoids in Hypericum perforatum, Pharmazie, 40, 585
Durán, 1986, Hypericin and its photodynamic action, Photochem. Photobiol., 43, 677, 10.1111/j.1751-1097.1986.tb05646.x
Ereshefsky, 1999, Determination of St John's wort differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology
Ernst, 1998, Adverse effects profile of the herbal antidepressant St John's wort (Hypericum perforatum L.), Eur J. Clin. Pharmacol., 54, 589, 10.1007/s002280050519
2000, European Pharmacopoeia 2000
European Scientific Cooperative on phytotherapy., 1996, St John's wort. Monographs on the medicinal use of plant drugs
Fiebich, 1999, Antibacterial activity of hyperforin from St John's wort, Lancet, 354, 777, 10.1016/S0140-6736(05)76019-0
Franklin, 1999, Neuroendocrine evidence for dopaminergic actions of hypericum extract (LI 160) in healthy volunteers, Biol. Psychiatry, 46, 581, 10.1016/S0006-3223(99)00102-X
Friede, 1998, Alltagssicherheit eines pflanzlichen Antidepressivums aus Johannis kraut, Fortschritte der Medizin, 116, 131
Friede, 2000, Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F32.1) with Hyperici herba [abstract]
Gambarana, 1999, Efficacy of an Hypericum perforatum (St John's wort) extract in preventing and reverting a condition of escape deficit in rats, Neuropsychopharmacology, 21, 247, 10.1016/S0893-133X(99)00027-5
Garrett, 1982, Consumption of poisonous plants (Senecio jacobaea, Symphytum officinale, Pteridium aquilinum, Hypericum perforatum) by rats: chronic toxicity, mineral metabolism, and hepatic drug-metabolizing enzymes, Toxicol. Lett., 10, 183, 10.1016/0378-4274(82)90072-8
Gewertz, 1999, Determination of the differential effects of St John's wort on the CYP1A2 and NAT2 metabolic pathways using caffeine probe methodology
Giese, 1980, Hypericism, Photochem. Photobiol., 5, 229
Gobbi, 1999, Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex, Naunyn-Schmiedebergs Arch. Pharmacol, 360, 262, 10.1007/s002109900073
Gordon, 1998, SSRIs and St John's wort: possible toxicity, Am. Fam. Phys., 57, 950
Grube, 1999, St John's wort extract: efficacy for menopausal symptoms of psychological origin, Adv. Ther., 16, 177
Grube, 1997, Use of a hypericum extract in mild, transient depressive mood disorders, Eur. J. Clin. Res., 9, 293
Grujic-Vasic, 1986, The examining of isolated tannins and their astringent effect, Planta Med, 52, 67
Grush, 1998, St John's wort during pregnancy, J. Am. Med. Assoc., 280, 1566, 10.1001/jama.280.18.1566
Gulick, 1999, Phase I studies of hypericin, the active compound in St John's wort, as an antiretroviral agent in HIV-infected adults, Ann. Intern. Med., 130, 510, 10.7326/0003-4819-130-6-199903160-00015
Harrer, 1999, Comparison of equivalence between the St John's wort extract LoHyp-57 and fluoxetine, Arzneim-Forsch, 49, 289
Helgason, 2000, The effects of St John's wort (Hypericum perforatum) on NK cell activity in vitro, Immunopharmacology, 46, 247, 10.1016/S0162-3109(99)00187-3
Hoelzl, 1987, St John's wort (Hypericum perforatum L.). HPLC analysis of the main components and their variability in a population, Deutsch Apoth Ztg, 127, 1227
Holsboer-Trachsler, 1999, Efficacy and tolerability of the hypericum special extract LI 160 in young and elderly outpatients with depressive disorders: a drug monitoring study, Eur Neuropsychopharmacology, 9, S226, 10.1016/S0924-977X(99)80164-3
Hottenrot, 1997, The influence of vitamin E and extract from hypericum on the endurance capacity of competitors. A placebo-controlled double-blind study with long-distance runners and triathletes, Deutsche seitschrift für Sportmedizin, 48, 22
Hudson, 1991, Antiviral activities of hypericin, Antiviral Res, 15, 101, 10.1016/0166-3542(91)90028-P
1989, Hypericin - a plant extract with anti-HIV activity, Scrip, 1415, 29
Isenberg, 1998, Herbal products are driving supplement industry growth, Herbalgram, 42, 65
Johne, 1999, Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum), Clin. Pharmacol. Ther., 66, 338, 10.1053/cp.1999.v66.a101944
Johnston, 1999, Sun trap, New Scientist, 24
Kalb, 2000, Hypericum extract WS 5572 is effective and safe in the treatment of mild to moderate depression [abstract]
Kamuhabwa, 2000, Investigation of the absorption of hypericin into the skin of hairless mice, J. Pharm. Pharmacol., 52, 487, 10.1211/0022357001774264
Kamuhabwa, 2000, Photodynamic activity of hypericin in human urinary bladder carcinoma cells, Anticancer Res., 20, 2579
Kasper, 1997, Treatment of seasonal affective disorder (SAD) with hypericum extract, Pharmacopsychiatry, 30, 89, 10.1055/s-2007-979526
Käufeler, 2000, Efficacy and tolerability of the St John's wort extract (Ze 117) in comparison with placebo, imipramine and fluoxetine for the treatment of mild to moderate depression according to ICD-10 [abstract]
Kerb, 1997, Urinary 6-beta-hydroxycortisol excretion rate is affected by treatment with hypericum extract, Eur. J. Clin. Pharmacol., 52, 607
Kim, 1999, St John's wort for depression. A meta-analysis of well-defined clinical trials, J. Nerv. Ment. Dis., 187, 532, 10.1097/00005053-199909000-00002
Koch, 2000, Hyperforin stimulates intracellular calcium mobilisation and enhances extracellular acidification in DDT1-MF2 smooth muscle cells [abstract]
Kumar, 2000, Effect of Indian Hypericum perforatum Linn on animal models of cognitive dysfunction, J. Ethnopharmacol., 72, 119, 10.1016/S0378-8741(00)00216-6
Laakman, 2000, Effects of hypericum extract on adenohypophysial hormone secretion and catecholamine metabolism [abstract]
Laakmann, 1998, St John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy, Pharmacopsychiatry, 31, 54, 10.1055/s-2007-979346
Lane-Brown, 2000, Photosensitivity associated with herbal preparations of St John's wort (Hypericum perforatum), Med J Aust, 172, 302, 10.5694/j.1326-5377.2000.tb123965.x
Lantz, 1999, St John's wort and antidepressant drug interactions in the elderly, J. Geriatr. Psychiatry Neurol., 12, 7, 10.1177/089198879901200103
Lavie, 1989, Studies of the mechanisms of the antiretroviral agents hypericin and pseudohypericin, Proc. Natl Acad. Sci., 86, 5963, 10.1073/pnas.86.15.5963
Lemmer, 1999, Wirksamkeit im Alter und bei chronischen Verlaufsformen, Münch Med Wschr Fortschr Med., 141, 43
Lenoir, 1999, A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L., Phytomedicine, 6, 141, 10.1016/S0944-7113(99)80001-4
Linde, 1999, Commentary: Has hypericum found its place in antidepressant treatment, BMJ, 319, 1539
Linde, 2001, St John's wort for depression (Cochrane Review), The Cochrane Library
Linde, 1996, St John's wort for depression - an overview and meta-analysis of randomised clinical trials, BMJ, 313, 253, 10.1136/bmj.313.7052.253
Liu, 2000, Hypericin and photodynamic therapy decreases human pancreatic cancer in vitro and in vivo, J. Surg. Res., 93, 137, 10.1006/jsre.2000.5949
Lopez-Bazzocchi, 1991, Antiviral activity of the photoactive plant pigment hypericin, Photochem. Photobiol., 54, 95, 10.1111/j.1751-1097.1991.tb01990.x
Markowitz, 2000, Effect of St John's wort (Hypericum perforatum) on cytochrome P450 2D6 and 3A4 activity in healthy volunteers, Life Sci., 66, 133, 10.1016/S0024-3205(99)00659-1
Mathis, 1964, Étude chimio-taxonomique du genre Hypericum - II. Identification de constituants de diverses huiles essentielles d'Hypericum, Phytochemistry, 3, 115, 10.1016/S0031-9422(00)84003-0
Mathis, 1964, Étude chimio-taxonomique du genre Hypericum - IV. Repartition des sesquiterpenes, des alcools mono-terpeniques et des aldehydes satures dans les huiles essentielles d'Hypericum, Phytochemistry, 3, 377, 10.1016/S0031-9422(00)83620-1
Mathis, 1964, Étude chimio-taxonomique du genre Hypericum - V. Identification de quelques constituants non volatils d'Hypericum perforatum L, Phytochemistry, 3, 379, 10.1016/S0031-9422(00)83621-3
Maurer, 1999, Interaction of St John's wort extract with phenprocoumon [abstract], Eur. J. Clin. Pharmacol., 55, A22
Meier, 1997, Wirksamkeit und Verträglichkeit eines standardisierten Johanniskraut-Vollextraktes (Ze 117) bei Patienten mit depressiver Symptomatik unterschiedlicher Schweregrade - eine Anwendungsbeobachtung, Forsch Komplementärmed, 4, 87
Melzer, 1988, Proanthocyanidins from Hypericum perforatum: Effects on isolated pig coronary arteries, Planta Med., 54, 572, 10.1055/s-2006-962578
Meruelo, 1988, Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin, Proc. Natl Acad. Sci., 85, 5230, 10.1073/pnas.85.14.5230
Mills, 2000, Principles and Practice of Phytotherapy
Mishenkova, 1975, Antiviral properties of St John's wort and preparations produced from it, Tr S'ezda Mikrobiol Ukr, 222
Moore, 2000, St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor, Proc. Natl Acad. Sci., 97, 7500, 10.1073/pnas.130155097
Mueller, 1998, Effects of hypericum extract HYP811 in patients with psychovegetative disorders, Adv. Ther., 15, 255
Mueller, 1998, St John's wort for depressive disorders: results of an outpatient study with the hypericum preparation HYP811, Adv. Ther., 15, 109
Müller, 1997, Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity, Pharmacopsychiatry, 30, 102, 10.1055/s-2007-979528
Nahrstedt, 1997, Biologically active and other chemical constituents of the herb of Hypericum perforatum L, Pharmacopsychiatry, 30, 129, 10.1055/s-2007-979533
Nathan, 1999, The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L), Molecular Psychiatry, 4, 333, 10.1038/sj.mp.4000557
Nebel, 1999, Potential metabolic interaction between St John's wort and theophylline, Ann. Pharmacother., 33, 502, 10.1345/aph.18252
Newall, 1996, Herbal Medicines. A Guide for Health-care Professionals, 1st
Nierenberg, 1999, Mania associated with St John's wort, Biol. Psychiatry, 46, 1707, 10.1016/S0006-3223(99)00233-4
O'Breasil, 1998, Hypomania and St John's wort, Can. J. Psychiatry, 43, 746
Obach, 2000, Inhibition of human cytochrome P450 enzymes by constituents of St John's wort, an herbal preparation used in the treatment of depression, J. Pharmacol. Exp. Ther., 294, 88
Ollivier, 1985, Separation et identification des acides phenols par chromatographie liquide haute performance et spectroscopie ultra-violette. Application à la pariétaire (Parietaria officinalis L.) et au millepertuis (Hypericum perforatum L.), J. Pharm. Belg., 40, 173
Ondrizek, 1999, Inhibition of human sperm motility by specific herbs used in alternative medicine, J. Assist. Reprod. Genet., 16, 87, 10.1023/A:1022568823262
Panocka, 2000, Effects of Hypericum perforatum on ethanol intake, and on behavioural despair: a search for the neurochemical systems involved, Pharmacol. Biochem. Behav., 66, 105, 10.1016/S0091-3057(00)00193-3
Panossian, 1996, Immunosuppressive effects of hypericin on stimulated human leucocytes: inhibition of the arachidonic acid release, leuko-triene B4 and interleukin-1 production and activation of nitric oxide formation, Phytomedicine, 3, 19, 10.1016/S0944-7113(96)80005-5
Parfitt, 1999, Martindale The Complete Drug Reference, 32nd
Philipp, 1999, Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks, BMJ, 319, 1534, 10.1136/bmj.319.7224.1534
Piscitelli, 2000, Indinavir concentrations and St John's wort, Lancet, 355, 547, 10.1016/S0140-6736(99)05712-8
Pitisuttithum, 1996, International Conference on AIDS, 11, 285
Rey, 1998, Hypericum perforatum (St John's wort) in depression: pest or blessing, Med. J. Aust., 169, 583, 10.5694/j.1326-5377.1998.tb123424.x
Rezvani, 1999, Attenuation of alcohol intake by extract of Hypericum perforatum (St John's wort) in two different strains of alcohol-preferring rats, Alcohol Alcohol., 34, 699, 10.1093/alcalc/34.5.699
Roby, 2000, St John's wort: effect on CYP3A4 activity, Clin. Pharmacol. Ther., 67, 451, 10.1067/mcp.2000.106793
Ruschitzka, 2000, Acute heart transplant rejection due to Saint John's wort, Lancet, 355, 548, 10.1016/S0140-6736(99)05467-7
Schellenberg, 1998, Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG, Pharmacopsychiatry, 31, 44, 10.1055/s-2007-979345
Schempp, 1999, Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady-state administration of Hypericum perforatum extract (St John's wort), Skin Pharmacol. Appl. Skin Physiol., 12, 299, 10.1159/000066256
Schempp, 1999, Antibacterial activity of hyperforin from St John's wort, against multiresistant Staphylococcus aureus and gram-positive bacteria, Lancet, 353, 2129, 10.1016/S0140-6736(99)00214-7
Schempp, 2000, Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells, Br. J. Dermatol., 142, 979, 10.1046/j.1365-2133.2000.03482.x
Schempp, 2000, Effect of topical application of Hypericum perforatum extract (St John's wort) on skin sensitivity to solar simulated radiation, Photodermatol. Photoimmunol. Photomed., 16, 125, 10.1034/j.1600-0781.2000.d01-18.x
Schey, 2000, Photooxidation of lens alpha-crystallin by hypericin, Photochem. Photobiol., 72, 200, 10.1562/0031-8655(2000)072<0200:POLCBH>2.0.CO;2
Schrader, 2000, Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study mild-moderate depression, Int. J. Clin. Psychopharmacol., 15, 61, 10.1097/00004850-200015020-00001
Schrader, 1998, Hypericum treatment of mild-moderate depression in a placebo-controlled study. A prospective, double-blind, randomized, placebo-controlled, multi-centre study, Human Psychopharmacol., 13, 163, 10.1002/(SICI)1099-1077(199804)13:3<163::AID-HUP5>3.0.CO;2-I
Schulz, 1998, Rational Phytotherapy. A Physicians' Guide to Herbal Medicine
Sharpley, 1998, Antidepressant-like effect of Hypericum perforatum (St John's wort) on the sleep polysomnogram, Psychopharmacology, 139, 286, 10.1007/s002130050718
Shiplochliev, 1981, Extracts from a group of medicinal plants enhancing the uterine tonus, Vet Med Nauki, 18, 94
Shipochliev, 1981, Anti-inflammatory action of a group of plant extracts, Vet. Med. Nauki., 18, 87
Siegers, 1993, Zur Frage der Phototoxizität von Hypericum, Nervenheilkunde, 12, 320
Singer, 1999, Hyperforin, a major antidepressant constituent of St. John's wort, inhibits serotonin uptake by elevating free intracellular Na+, J. Pharmacol. Exp. Ther., 290, 1363
Singer, 2000, Hyperforin alters free intracellular H+ and Na+ concentration in human platelets [abstract]
Staffeldt, 1994, Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers, J. Geriatr. Psychiatry Neurol., 7, S47, 10.1177/089198879400701s13
Steinbeck-Klose, 1993, Successful long-term treatment over 40 months of HIV-patients with intravenous hypericin [abstract], International Conference on AIDS, 9, 470
Stevinson, 1999, Safety of hypericum in patients with depression. A comparison with conventional antidepressants, CNS Drugs, 11, 125, 10.2165/00023210-199911020-00004
Stevinson, 2000, A pilot study of Hypericum perforatum, for the treatment of premenstrual syndrome, Br. J. Obstet. Gynaecol., 107, 870, 10.1111/j.1471-0528.2000.tb11085.x
Stevinson, 1998, Hypericum for fatigue - a pilot study, Phytomedicine, 5, 443, 10.1016/S0944-7113(98)80040-8
Suzuki, 1984, Inhibition of monoamine oxidase by hypericin, Planta Med., 50, 272, 10.1055/s-2007-969700
Tahara, 1999, The antidepressant hypericin inhibits progression of experimental proliferative vitreoretinopathy, Curr. Eye Res., 19, 323, 10.1076/ceyr.19.4.323.5302
Takahashi, 1989, Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity, Biochem. Biophys. Res. Comm., 165, 1207, 10.1016/0006-291X(89)92730-7
Taylor, 2000, An open-label trial of St John's wort (Hypericum perforatum) in obsessive-compulsive disorder, J. Clin. Psychiatry, 61, 575, 10.4088/JCP.v61n0806
Thiede, 1994, Inhibition of MAO and COMT by Hypericum extracts and hypericin, J. Ger. Psychiatry Neurol., 7, S54, 10.1177/089198879400701s14
Trifunovic, 1998, Oxidation products of hyperforin from Hypericum perforatum, Phytochemistry, 49, 1305, 10.1016/S0031-9422(97)00903-5
Uebelhack, 2000, In vitro effects of hypericum extract and hyperforin on 5HT uptake and efflux in human blood platelets [abstract]
Vandenbogaerde, 2000, Evidence that total extract of Hypericum perforatum affects exploratory behaviour and exerts anxiolytic effects in rats, Pharmacol. Biochem. Behav., 65, 627, 10.1016/S0091-3057(99)00233-6
Vanhaelen, 1983, Quantitative determination of biologically active constituents in medicinal plant crude extracts by thin-layer chromatography-densitometry, J. Chromatogr., 281, 263, 10.1016/S0021-9673(01)87884-5
Verotta, 1999, Furohyperforin, a prenylated phloroglucinol from st. John's wort (Hypericum perforatum), J. Nat. Prod., 62, 770, 10.1021/np980470v
Verotta, 2000, Hyperforin analogues from St John's wort (Hypericum perforatum), J. Nat. Prod., 63, 412, 10.1021/np9903752
Vitiello, 1999, Hypericum perforatum extracts as potential anti-depressants, J. Pharm. Pharmacol., 51, 513, 10.1211/0022357991772781
Voss, 1999, Antibacterial activity of hyperforin from St John's wort, Lancet, 354, 777, 10.1016/S0140-6736(05)76018-9
Weber, 1994, The antiviral agent hypericin has in vitro activity against HSV-1 through non-specific association with viral and cellular membranes, Antiviral Chemistry & Chemotherapy, 5, 83, 10.1177/095632029400500204
Wheatley, 1999, Hypericum in seasonal affective disorder (SAD), Curr. Med. Res. Opin., 15, 33, 10.1185/03007999909115171
Woelk, 2000, Comparison of St John's wort and imipramine for treating depression:randomised controlled trial, BMJ, 321, 536, 10.1136/bmj.321.7260.536
Woelk, 1994, Benefits and risks of the hypericum extract LI 160. Drug monitoring study with 3250 patients, J. Geriatr. Psychiatry Neurol., 7, 34, 10.1177/089198879400701s10
Wonnemann, 2000, Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St John's wort: the role of amiloride sensitive sodium conductive pathways, Neuropsychopharmacology, 23, 188, 10.1016/S0893-133X(00)00102-0
Wood, 1990, Antiviral activity of naturally occurring anthraquinones and anthraquinone derivatives, Planta Med., 56, 651, 10.1055/s-2006-961304
Yu, 2000, Effect of the Hypericum perforatum extract on serotonin turnover in the mouse brain, Pharmacopsychiatry, 33, 60, 10.1055/s-2000-7970